Select Page

5th International

Lung Cancer Summit


Registration to open on 1 July 2023

Our Chairs Invite You To Join!

Following the great success of the virtual International Lung Cancer Summit (ILCS), we look forward to welcoming you to the 5th edition of this interactive hybrid meeting. Similar to recent years, the ILCS will showcase the latest discoveries and advances performed towards the treatment of lung cancer. The conference will leverage digital channels to provide exceptional outreach and opportunities for delegates from Medical Offices, Universities and Institutes to interact with world-class Medical Oncologists and Industry Professionals working in the field of lung cancer treatment and research.
The ILCS constitutes an ideal platform to share knowledge and seamless treatment procedures with our local and international speakers from the USA, Spain, UK, Italy, Netherlands, Germany , Austria and Switzerland.

Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Alfredo Addeo, MD

Alfredo Addeo, MD, is a Consultant Medical Oncologist at the University Hospital of Geneva, Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Impressions of the ILCS 2022


5 SGMO CME Credits

Our Tentative Program

10th November 2023

All times are in Central European Time


Welcome by Chairs

Solange Peters & Alfredo Addeo


What tests are must-haves in lung cancer diagnostics today, and what’s next for tomorrow

Anne Schultheis (Germany)


Current standards and future perspectives in targeting EGFR and ALK

Zofia Piotrowska (USA)


Rare But Actionable: available therapies for RET, METex14 and NTRK

Maximilian Hochmair (Austria)


Open discussion & coffee break


KRAS, HER2 and the emergence of more actionable mutations

Tina Cascone (USA)


SCLC: New treatment paradigms and a glimpse into our treatment options of tomorrow

Kaushal Parikh (USA)


Latest advances in thoracic surgery for NSCLC

Jean Y. Perentes (Switzerland)



Neo-Adjuvant vs. Adjuvant IO in early NSCLC

Thomas Newsom-Davis (UK)
Antonio Passaro (Italy)



Open discussion & coffee break


IO in NSCLC: are there differences between the PD-(L)1 inhibitors?

Rosario García Campelo (Spain)


Beyond PD-1 and CTLA-4 inhibition: Where is IO headed in non-oncogenic NSCLC

Lizza Hendriks (Netherlands)


Open Questions, Patient Cases & Guidelines

Panel Discussion With All

for sponsoring opportunities, please contact us at








Follow Us For The Latest News on Twitter & LinkedIn